Final Clinical Tests of Skywalk Pre-Production Series Start at Rehaklinik Tschugg
Final clinical tests of Skywalk’s pre-production series have started at Rehaklinik Tschugg in Switzerland. From December 11, 2025 to January 8, 2026, the system is being evaluated in real-world neurorehabilitation settings as a key step toward market launch.
Tschugg, Switzerland – December 11, 2025
The final clinical testing phase of Skywalk, autonomyo’s mechanically assisted body-weight support system for gait rehabilitation, has started at Rehaklinik Tschugg in Switzerland. The tests are conducted using the pre-production series of Skywalk and run from December 11, 2025 to January 8, 2026.
This phase represents a key milestone on the path toward market launch. The objective is to validate Skywalk under real-world clinical conditions, focusing on usability, safety, workflow integration, and therapeutic applicability in daily neurorehabilitation practice.
Objectives of the Clinical Test Phase
During the testing period, Skywalk is being used by experienced physiotherapists in structured inpatient therapy sessions. The evaluation focuses on:
Safe verticalization and progressive weight-bearing of patients with severe mobility impairments
Support of early gait training in neurological rehabilitation
Ease of handling and setup for therapists
Integration into existing clinical workflows and therapy concepts
System robustness and reliability of the pre-production units
Insights gathered during this phase will be used to finalize the device configuration ahead of series production and regulatory market entry.
Collaboration with Rehaklinik Tschugg
Rehaklinik Tschugg is internationally recognized for its expertise in neurological rehabilitation. Conducting the final clinical tests in this environment enables direct feedback from clinical specialists and therapists working with complex patient profiles in daily practice.
“Testing the pre-production series in a leading rehabilitation clinic is a critical step for us,” said Fabian Bischof, Co-Founder of autonomyo. “It allows us to ensure that Skywalk meets the practical requirements of therapists and delivers meaningful therapeutic value for patients.”
Advancing Toward Market Launch
Skywalk is designed as a compact, space-efficient, and cost-effective solution for supported gait therapy, addressing limitations of large, space-intensive robotic systems and enabling early mobilization in both inpatient and outpatient settings.
The completion of this final clinical testing phase is a major step toward the planned market launch of Skywalk in Europe and the United States in the first half of 2026.